Rat and human primary proximal tubule epithelial cells allow for cross-species comparisons of drug-induced nephrotoxicity in vitro.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Archives of Toxicology

• Publication date

  2026-02-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00204-026-04309-yPMID 41699311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Human and rat renal proximal tubule in vitro models for ADME applications

  2025cited by this paper
• A novel in vitro high-content imaging assay for the prediction of drug-induced lung toxicity

  2024cited by this paper
• Zoledronic acid and ibandronate-induced nephrotoxicity in 2D and 3D proximal tubule cells derived from human and rat.

  2023cited by this paper
• Renal Organic Anion Transporters 1 and 3 In Vitro: Gone but Not Forgotten

  2023cited by this paper
• Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.

  2021cited by this paper
• Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

  2021cited by this paper
• Justification for species selection for pharmaceutical toxicity studies

  2020cited by this paper
• Kidney Transporters and Drug-Induced Injury in Drug Development

  2020cited by this paper
• Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicity.

  2020cited by this paper
• Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics

  2019cited by this paper
• Kidney Safety Assessment: Current Practices in Drug Development.

  2019cited by this paper
• Emerging In Vitro Systems to Screen and Predict Drug-Induced Kidney Toxicity.

  2019cited by this paper
• A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery

  2018cited by this paper
• Impact of a five-dimensional framework on R&D productivity at AstraZeneca

  2018cited by this paper
• Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity

  2018cited by this paper
• A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity

  2016cited by this paper
• Advances in Predictive Toxicology for Discovery Safety through High Content Screening.

  2016cited by this paper
• An analysis of the attrition of drug candidates from four major pharmaceutical companies

  2015cited by this paper
• Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir.

  2015cited by this paper
• Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.

  2015cited by this paper
• Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.

  2014cited by this paper
• Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.

  2014cited by this paper
• Tenofovir Disoproxil Fumarate

  2012cited by this paper
• Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics

  2012cited by this paper
• Evaluation of drugs with specific organ toxicities in organ-specific cell lines.

  2012cited by this paper
• Differences in Rat Models Used in Routine Toxicity Studies

  2011cited by this paper
• Tenofovir Renal Proximal Tubular Toxicity Is Regulated By OAT1 and MRP4 Transporters

  2011cited by this paper
• Impact and prevalence of safety pharmacology-related toxicities throughout the pharmaceutical life cycle

  2010cited by this paper
• Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.

  2008cited by this paper
• Functional Involvement of the Organic Cation Transporter 2 (rOct2) in the Renal Uptake of Organic Cations in Rats

  2008cited by this paper
• Compound Cytotoxicity Profiling Using Quantitative High-Throughput Screening

  2007cited by this paper
• Drug-associated renal dysfunction and injury

  2006cited by this paper
• Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.

  2006cited by this paper
• Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)

  2006cited by this paper
• High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening

  2006cited by this paper
• Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.

  2005cited by this paper
• Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.

  2005cited by this paper
• Acute renal failure in critically ill patients: a multinational, multicenter study.

  2005cited by this paper
• Cellular and molecular aspects of drug transport in the kidney.

  2000cited by this paper
• Zomepirac: A Review of its Pharmacological Properties and Analgesic Efficacy

  1982cited by this paper
• Clinical kinetics of intact cisplatin and some related species

  1981cited by this paper
• Clinical kinetics on intact cisplatin and some related species.

  1981cited by this paper

• No citing papers are available for this paper.